US Stock MarketDetailed Quotes
NTLA Intellia Therapeutics
- 22.380
- +1.070+5.02%
Close Aug 8 16:00 ET
- 22.500
- +0.120+0.54%
Post 19:59 ET
2.27BMarket Cap-4083P/E (TTM)
22.390High20.800Low1.56MVolume22.080Open21.310Pre Close34.22MTurnover1.64%Turnover RatioLossP/E (Static)101.58MShares39.14052wk High2.34P/B2.13BFloat Cap19.37052wk Low--Dividend TTM95.24MShs Float202.730Historical High--Div YieldTTM7.46%Amplitude9.180Historical Low21.881Avg Price1Lot Size
Intellia Therapeutics Stock Forum
Sign in to post a comment
Cathie Wood has been busy this week. The Ark Invest co-founder, CEO, and ace stock picker added to five of her existing growth stocks on Wednesday. I covered two of those names yesterday. Let's dive into the other three purchases.
What's she buying now? Some of the names on her Wednesday shopping list included Advanced Micro Devices $Advanced Micro Devices (AMD.US)$ , Pinterest $Pinterest (PINS.US)$ , and Intellia Therapeutics $Intellia Therapeutics (NTLA.US)$ . Let's t...
What's she buying now? Some of the names on her Wednesday shopping list included Advanced Micro Devices $Advanced Micro Devices (AMD.US)$ , Pinterest $Pinterest (PINS.US)$ , and Intellia Therapeutics $Intellia Therapeutics (NTLA.US)$ . Let's t...
14
3
How does the biotech ecosystem support advancements in personalized medicine & genomics? ![]()
• Editing Genes | $CRISPR Therapeutics (CRSP.US)$ , $Intellia Therapeutics (NTLA.US)$ , $Beam Therapeutics (BEAM.US)$ , $Verve Therapeutics (VERV.US)$ , $Editas Medicine (EDIT.US)$
• Creating Therapies | $Prime Medicine (PRME.US)$ , $Sana Biotechnology (SANA.US)$
• Building DNA | $Twist Bioscience (TWST.US)$ , $Ginkgo Bioworks (DNA.US)$ , $Pacific Biosciences of California (PACB.US)$ , $Illumina (ILMN.US)$
• Dis...
• Editing Genes | $CRISPR Therapeutics (CRSP.US)$ , $Intellia Therapeutics (NTLA.US)$ , $Beam Therapeutics (BEAM.US)$ , $Verve Therapeutics (VERV.US)$ , $Editas Medicine (EDIT.US)$
• Creating Therapies | $Prime Medicine (PRME.US)$ , $Sana Biotechnology (SANA.US)$
• Building DNA | $Twist Bioscience (TWST.US)$ , $Ginkgo Bioworks (DNA.US)$ , $Pacific Biosciences of California (PACB.US)$ , $Illumina (ILMN.US)$
• Dis...
7
If you had invested $10,000 in Cathie Wood's $ARK Innovation ETF (ARKK.US)$ and Warren Buffett's Berkshire Hathaway $Berkshire Hathaway-B (BRK.B.US)$ at different time frames here's how much you'd have today.
When $ARKK launched in 2014
Total Returns:
$BRK.B $28.6K
$ARKK $27.4K
5 years ago
Total Returns:
$BRK.B $19.7K
$ARKK $11.7K
3 years ago
Total Returns:
$BRK.B $16.4K
$ARKK $3.3K
1 year ago
Total Returns:
$BRK.B $12.8K
$ARKK $12.4K
At the start of 2024
Total Returns:
$BR...
When $ARKK launched in 2014
Total Returns:
$BRK.B $28.6K
$ARKK $27.4K
5 years ago
Total Returns:
$BRK.B $19.7K
$ARKK $11.7K
3 years ago
Total Returns:
$BRK.B $16.4K
$ARKK $3.3K
1 year ago
Total Returns:
$BRK.B $12.8K
$ARKK $12.4K
At the start of 2024
Total Returns:
$BR...
+3
$Warren Buffett Portfolio (BK2999)$ $Berkshire Hathaway-A (BRK.A.US)$ $Berkshire Hathaway-B (BRK.B.US)$ $ARK Innovation ETF (ARKK.US)$ $Coinbase (COIN.US)$ $Apple (AAPL.US)$ $Bank of America (BAC.US)$ $American Express (AXP.US)$ $S&P 500 Index (.SPX.US)$ $CRISPR Therapeutics (CRSP.US)$ $Intellia Therapeutics (NTLA.US)$
2
2
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Insiders selling shares at low prices may signal expected stock weakness. The absence of insider buying and increased selling over the past year suggest the shares aren't cheap, making the company a cautious investment.
1
Columns Gene Editing: Is This "Turning Point in Medicine" a Potential Source of Blockbuster Revenue?
The first treatment based on CRISPR technology is poised to win FDA approval next month, offering hope to patients and opportunities to investors.
"A turning point in medicine"
Scientists have made significant progress in treating thousands of illnesses over the years, but finding cures for rare and deadly diseases remains a significant challenge. While treatments for inherited conditions like sickle cell...
"A turning point in medicine"
Scientists have made significant progress in treating thousands of illnesses over the years, but finding cures for rare and deadly diseases remains a significant challenge. While treatments for inherited conditions like sickle cell...
19
2
The future prospects of the company following disappointing price downfall despite revenue growth are now crucial. Long-term investors, however, made a 6% return each year if invested over five years, suggesting previous over-hype.
1
$ARK Innovation ETF (ARKK.US)$ $ARK Next Generation Internet ETF (ARKW.US)$ $ARK Autonomous Technology & Robotics ETF (ARKQ.US)$
ARK Invest’s 13F portfolio value increased from $11.54B to $14.55B this quarter.
They increased Tesla, Coinbase Global, Block, Unity Software, and Ginkgo Bioworks while decreasing Exact Sciences, Twilio, and NVIDIA during the quarter.
The top three positions are Tesla, Roku, and Zoom Video, and they add up to ~...
ARK Invest’s 13F portfolio value increased from $11.54B to $14.55B this quarter.
They increased Tesla, Coinbase Global, Block, Unity Software, and Ginkgo Bioworks while decreasing Exact Sciences, Twilio, and NVIDIA during the quarter.
The top three positions are Tesla, Roku, and Zoom Video, and they add up to ~...
9
1
Shopify Upgraded to Neutral From Sell by UBS
$Shopify (SHOP.US)$ Upgraded to Neutral From Sell, Price Target Upped to $64 From $34 at UBS.
Guggenheim Upgrades Cloudflare to Neutral
Guggenheim analyst John Difucci upgrades $Cloudflare (NET.US)$ from Sell to Neutral.
JPMorgan Upgrades Kellogg to Neutral, Raises Price Target to $72
JP Morgan analyst Ken Goldman upgrades $Kellanova (K.US)$ from Underweight to Neutral and raises the price target fro...
$Shopify (SHOP.US)$ Upgraded to Neutral From Sell, Price Target Upped to $64 From $34 at UBS.
Guggenheim Upgrades Cloudflare to Neutral
Guggenheim analyst John Difucci upgrades $Cloudflare (NET.US)$ from Sell to Neutral.
JPMorgan Upgrades Kellogg to Neutral, Raises Price Target to $72
JP Morgan analyst Ken Goldman upgrades $Kellanova (K.US)$ from Underweight to Neutral and raises the price target fro...
16
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
10baggerbamm : why is anybody even bothering with this woman she's been negative year-to-date she is no conviction she gives price targets pie in the sky and if she really believed in them she would not be selling these companies she's full of shit she made money one year one time everything else has been a disaster
tankeng : yes this woman has problems and arrogant
OhNowGombie : Another quack you mean? Totally out of her gourd too